Active Ingredient(s): Palivizumab
FDA Approved: * June 19, 1998
Pharm Company: * MEDIMMUNE
Category: Vaccination

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Synagis Overview

Palivizumab (brand name Synagis which is manufactured by MedImmune) is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV. In two phase III clinic...

Read more Synagis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Synagis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 100mg, 100mg/ml, 50mg, 50mg/ml
  • Vial: 100mg/vial, 50mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Synagis: (2 results)

Sorted by National Drug Code
  • 60574-4113 Synagis 100 mg/ml Intramuscular Injection, Solution by Medimmune, LLC
  • 60574-4114 Synagis 50 mg/.5ml Intramuscular Injection, Solution by Medimmune, LLC

Other drugs which contain Palivizumab or a similar ingredient: (1 result)

Related Synagis Topics:

side effects long term...

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 3 June 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA